BioCryst sees FY24 ORLADEYO revenue $430M-$435M
PremiumThe FlyBioCryst sees FY24 ORLADEYO revenue $430M-$435M
23h ago
BioCryst sees FY24 total product revenue guidance $443M-$448M
Premium
The Fly
BioCryst sees FY24 total product revenue guidance $443M-$448M
23h ago
BioCryst Pharmaceuticals (BCRX) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
BioCryst Pharmaceuticals (BCRX) Q3 Earnings Cheat Sheet
3d ago
BioCryst Begins Phase 1 Trial for Netherton Syndrome Treatment
PremiumCompany AnnouncementsBioCryst Begins Phase 1 Trial for Netherton Syndrome Treatment
1M ago
BioCryst begins enrollment for Phase 1 trial evaluating BCX17725
Premium
The Fly
BioCryst begins enrollment for Phase 1 trial evaluating BCX17725
1M ago
BioCryst Secures Major US Health Department Influenza Drug Deal
Premium
Company Announcements
BioCryst Secures Major US Health Department Influenza Drug Deal
1M ago
BioCryst reports inducement grants under Nasdaq listing rule
PremiumThe FlyBioCryst reports inducement grants under Nasdaq listing rule
2M ago
BioCryst price target raised to $16 from $15 at JMP Securities
Premium
The Fly
BioCryst price target raised to $16 from $15 at JMP Securities
3M ago
BioCryst price target raised to $7 from $6 at Barclays
Premium
The Fly
BioCryst price target raised to $7 from $6 at Barclays
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100